OINDPnews


Copley Scientific banner

Business

Philips-Medisize to be acquired by Golden State Capital

Device manufacturer Phillips-Medisize has announced that it will be acquired by Golden Gate Capital for an undisclosed amount. According to the announcement, Matt Jennings will remain as President and CEO, and the company will keep its headquarters in Wisconsin. The company, which offers design and manufacturing services for medical devices, including inhalers, has … [Read more...] about Philips-Medisize to be acquired by Golden State Capital

New patents for Discovery Labs’ aerosol surfactant and delivery system

Discovery Laboratories has announced that the US Patent and Trademark Office (USPTO) has issued the company a new patent titled "Ventilation Circuit Adaptor and Proximal Aerosol Delivery System" (Patent No. 8,701,658) and Notices of Allowance for two patents titled "Lyophilization of Synthetic Liposomal Pulmonary Surfactant" (application nos.14/091,608 and … [Read more...] about New patents for Discovery Labs’ aerosol surfactant and delivery system

3M DDS to expand UK MDI facility

According to 3M Drug Delivery Systems, the company will increase the capacity of its Loughborough, UK MDI facility by more than 20%. No additional details were provided. 3M DDS VP of Inhalation Drug Delivery Marcello Napol said, “Since developing the first MDI almost 60 years ago, 3M has continued pioneering in inhalation drug delivery, and this expansion of our … [Read more...] about 3M DDS to expand UK MDI facility

Bayer acquires Afrin nasal spray

Merck has announced the sale of its Consumer Care division, which markets Afrin oxymetazoline nasal spray, to Bayer. According to Bayer, "The purchase price of USD 14.2 billion includes a payment associated with sales of Claritin and Afrin in certain countries where these products are still prescription-only." Bayer Chairman Marijn Dekkers cited Afrin as one of … [Read more...] about Bayer acquires Afrin nasal spray

Survey says US payers would pay more for treatment that reduces asthma exacerbations

Decision Resources Group says that a survey of US payers found that 90 percent said they would pay a premium for a new treatment that does a significantly better job of reducing asthma exacerbations than Xolair (omalizumab). The survey results are in a report titled "Asthma (Moderate to Severe): Amid Significant Unmet Need, What Magnitude of Efficacy and Safety Do … [Read more...] about Survey says US payers would pay more for treatment that reduces asthma exacerbations

VR1 presents poster on intranasal capsaicin for headache

The makers of a homeopathic capsaicin nasal spray are presenting a poster featuring "real-world patient case series analysis supporting the use of intranasal capsaicin as an effective rapid treatment for severe headache and migraine pain" at the 2014 American Academy of Neurology (AAN) Annual Meeting. VR1, Inc. recently launched an intranasal capsaicin product, … [Read more...] about VR1 presents poster on intranasal capsaicin for headache

Anoro Ellipta launched in the US

GSK and Theravance have announced the launch of Anoro Ellipta umeclidinium/vilanterol inhalation powder in the United States, triggering a $30 million milestone payment from Theravance to GSK. The FDA approved Anoro Ellipta for the treatment of COPD in December 2013. Senior VP of GSK's Respiratory Business Unit Jorge Bartolome commented, "We understand that COPD … [Read more...] about Anoro Ellipta launched in the US

OPKO Health acquires Inspiro Medical and its Inspiromatic DPI

US pharmaceutical company OPKO Health has announced that it will acquire Israeli device company Inspiro Medical whose only product is the Inspiromatic dry powder inhaler. In June 2013, Inspiro announced positive results from a study of the device used to deliver formoterol. OPKO CEO and Chairman Phillip Frost said, "We are pleased to add this next generation … [Read more...] about OPKO Health acquires Inspiro Medical and its Inspiromatic DPI